Search
cyclophosphamide/pentostatin/rituximab (PCR regimen)
Indications:
- chronic lymphocytic leukemia (91% response rate)
Dosage: 6 21 day cycles of:
- pentostatin 2 mg/m2
- cyclophosphamide 600 mg/m2
- rituximab 375 mg/m2
- rituximab administer 3X in 1st week of 1st cycle only
- filgrastim administered with each cycle
Adverse effects:
1) pancytopenia (34%)
2) infections (2%)
3) death uncommon
General
pharmacologic combination
References
- Kay NE et al,
Combination chemoimmunotherapy with pentostatin,
cyclophosphamide, and rituximab shows significant clinical
activity with low accompanying toxicity in previously
untreated B chronic lymphocytic leukemia.
Blood 2007, 109:405
PMID: 17008537
Components
cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]
pentostatin (Nipent, DCF, 2'deoxycoformycin)
rituximab (Rituxan, Mabthera, Truxima, Ruxience, Riabni)